Botulinum Toxin A in the preventive treatment of chronic migraine; experience in Argentine headache center

Fleni


N Larripa – M Grandinetti – D Calvo – V Nagel – MT Goicochea. Headache Clinic. Department of Neurology: Fleni

Introduction and objective

Chronic migraine (CM), is defined as at least 15 headache days per month, with a minimum of 8 of them with migraine features, during the last three months (ICHD). In 2010, the use of a Botulinum Toxin type A (BoNTA), was approved as a preventive treatment for this neurologic disease. Its use has spread and, currently, it corresponds to a pharmacological tool in patients with CM. Its main mechanism of action is by blocking the exocytosis of algogenic peptides and excitatory substances such as substance P, CGPR and glutamate, in the synaptic gap of nociceptive afferents. In our country there is scarce information published about the response to this treatment. The objective of this study is to describe our experience in the headache service in Argentina, with the administration of BoNTA as a preventive treatment for CM

Materials and methods

A retrospective analysis was performed by reviewing the digital medical records of all patients from the Headache Clinic, treated with BoNTA between January and December 2021. Patients ≥18 years old were included, with at least 1 application of BoNTA according to the dose and points included in the PREEMPT protocol. Epidemiological data, coexistence of acute headache medication overuse, duration of treatment (year of initiation, number of application), number of previous oral preventives received, evolution during treatment, number of headaches days per month, days of analgesics per month, were evaluated. We consider non responder patients if they had less than 30% reduction of headache days per month after 3 treatment cycles. The review of adverse events and patient reported wearing off effect of the therapeutic benefit of BoNTA was registered.For data analysis, the STATA/14.0 program was used.



In local clinical practice BoNTA has an important role in the treatment of CM, high percentage of patients reduce the headache day per month and days of acute headache medication. It is an effective and well tolerated treatment for CM

Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P, Martelletti P. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018 Sep 26;19(1):91. doi: 10.1186/s10194-018-0921-8. PMID: 30259200; PMCID: PMC6755553. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebocontrolled phases of the PREEMPT clinical program. Headache. 2010 Jun;50(6):921-36. doi: 10.1111/j.1526-4610.2010.01678.x. Epub 2010 May 7. PMID: 20487038.